Relapsed Multiple Myeloma - Pipeline Review, H1 2015, New Report Launched

Relapsed Multiple Myeloma - Pipeline Review, H1 2015 report provides an overview of the Relapsed Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publishert’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publishert’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Spanning over 438 pages, “Relapsed Multiple Myeloma - Pipeline Review, H1 2015” report covers the Introduction, Relapsed Multiple Myeloma Overview, Therapeutics Development, Drug Profiles, Appendix. The report covered companies are - 4SC AG, AB Science, AbbVie Inc., Acceleron Pharma, Inc., Acetylon Pharmaceuticals, Inc., Altor BioScience Corporation, Arno Therapeutics, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., Biotest AG, Bristol-Myers Squibb Company, Celgene Corporation

For further information on this report, please visit- http://mrr.cm/4ne

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases